Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial - Test2 - elhamkhani - TriplyDB

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q28283107

about

sameAs

A review of anti-inflammatory agents for symptoms of schizophrenia Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials The role of inflammation in schizophrenia Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment The cytokine model of schizophrenia: emerging therapeutic strategies Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects Viral infection, inflammation and schizophrenia The Application of Multiplex Biomarker Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Application of Proteomic Techniques for Improved Stratification and Treatment of Schizophrenia Patients.Evidence for an immune role on cognition in schizophrenia: a systematic review Theranostic Biomarkers for Schizophrenia Transcriptome sequencing study implicates immune-related genes differentially expressed in schizophrenia: new data and a meta-analysis.Immunological aspects of the treatment of depression and schizophrenia.Methylation patterns in whole blood correlate with symptoms in schizophrenia patients.Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume.Add-on clinical effects of simvastatin and ondansetron in patients with schizophrenia stabilized on antipsychotic treatment: pilot study Effectiveness and tolerance of anti-inflammatory drugs' add-on therapy in major mental disorders: a systematic qualitative review.Anti-inflammatory effects of chronic aspirin on brain arachidonic acid metabolites.Biomarkers and clinical staging in psychiatry Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness Schizophrenia: a systemic disorder Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia Imaging brain signal transduction and metabolism via arachidonic and docosahexaenoic acid in animals and humans.Low-dose aspirin (acetylsalicylate) prevents increases in brain PGE2, 15-epi-lipoxin A4 and 8-isoprostane concentrations in 9 month-old HIV-1 transgenic rats, a model for HIV-1 associated neurocognitive disorders.Expression QTL analysis of top loci from GWAS meta-analysis highlights additional schizophrenia candidate genes Immune system gene dysregulation in autism and schizophrenia.A myelin gene causative of a catatonia-depression syndrome upon aging.Can bipolar disorder be viewed as a multi-system inflammatory disease?Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.Higher Plasma S100B Concentrations in Schizophrenia Patients, and Dependently Associated with Inflammatory Markers.Does Systemic Inflammation Play a Role in Pediatric Psychosis?Proteomic profiling in schizophrenia: enabling stratification for more effective treatment.Effect of epigallocatechin gallate supplementation in schizophrenia and bipolar disorder: an 8-week, randomized, double-blind, placebo-controlled study.Elevated peripheral cytokines characterize a subgroup of people with schizophrenia displaying poor verbal fluency and reduced Broca's area volume.Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials RETRACTED: Increased neuroinflammatory and arachidonic acid cascade markers, and reduced synaptic proteins, in the postmortem frontal cortex from schizophrenia patients

P2860

Q22241827-786DAD2D-1A6F-4E81-9DFA-69F71446B75F Q24630651-46FC1EBB-12DB-4D05-B724-440A431F3423 Q26741541-2DE30116-308B-4719-9EA6-A8EABE7BBA7D Q26779719-6239C130-A351-4F65-B077-BFDEC0124995 Q26781620-22B85E2F-8456-422D-84F8-BF9C5735FA6A Q26865996-86116694-2709-4ECC-B507-D47ED8894E2F Q28077391-24039393-C78D-4E86-89A0-19BDD749B3DC Q28299995-3E65D7A4-963E-4EAB-8A9E-02311269EC9F Q28657600-14D057C7-C20E-4B1A-917D-3D6E7CE00253 Q30440507-5480CFEC-C858-447B-9B3A-864455624788 Q33451672-0C82C230-D3C8-48AF-8F11-79DF9A084DCE Q33453744-D12A257E-39CB-4E31-8E93-317E99CD6F8A Q33621692-1D0FF2A8-FC8A-4E27-8725-AD9AB12140C7 Q33624412-CFA3D85C-1BC9-4533-A294-FEBAB702EF11 Q33635637-57A865D8-3B7A-4340-B0F4-0988D45B8C93 Q33721031-A3F02129-7FF1-4EA3-90BA-71F1A7BAF818 Q33762454-79315BAF-1EF6-4B0B-86C8-00D935B89C3F Q33849008-5F32A9F6-E6EC-4DC1-BBE3-B9887DC67500 Q33937341-4817C35C-83D4-453A-8B0F-E3880A4449E1 Q34384181-4D3A4122-3349-4E4E-AC13-B02F039FF46E Q34444465-0E4C368F-86FF-4BCE-BED9-6B04188D6AF6 Q34447051-1C62DED0-4166-4DDA-A6FC-13CC0631BBEE Q34626598-F7815632-92D6-424C-AD0D-AD4EA24E791D Q35323907-07D1794E-039B-4624-A69F-C0038BE2C6B9 Q35369617-1B12F1F1-2C4C-403A-B708-A161F80516A7 Q35742545-CED1525D-4924-41C4-BDD8-937D859C543D Q36035835-806B3D28-2A7E-4801-99AB-BDCA770A443F Q36170457-0A29F427-3FA1-4766-AA14-03090FD00C77 Q36213513-51808A79-1EDA-44E3-BF82-05159B28A50E Q36238656-375890A8-535A-4EE5-A2E2-CE2D6194DC4A Q36401142-0AEA7C95-7878-49D3-99FE-BFD67113E9A0 Q36661099-7C37726E-A859-409E-8455-64AD2A78573C Q36930839-8FB9A75B-D72B-4EC6-AAAB-94C596942CA9 Q36986134-C53981B9-8AA7-4BF8-83D2-8E1F2EF900DB Q36986370-18BBE4A0-7AD3-40BA-A247-A44B55E20C14 Q36998471-2C2A6C28-765E-42BF-8387-9F944110FA87 Q37079070-7BC90F6B-3354-40D5-AAAB-CB5176A81771 Q37124980-64E08355-C2E6-43B8-A6D5-C26D0144F06D Q37228346-B83D6750-4A2F-4B25-B2A3-DE2D09A57E18 Q37267763-562A984E-851B-4A1C-881D-96232A334FA4

P2860

Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial

http://www.wikidata.org/entity/Q28283107

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@ast

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@en

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@nl

type

label

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@ast

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@en

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@nl

altLabel

Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders

@en

prefLabel

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@ast

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@en

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@nl

P1433

Q28283107-11740E6E-2D1B-4445-9C13-941A2D813AF8

P1476

Q28283107-2F7E7568-5349-486D-8124-9D2CAA42DFAC

Q28283107-8AA1F568-3A74-448E-918F-8A140199CC3F

P2093

Q28283107-01E1AFCA-C7FA-4EF9-A2F1-AB225F7DE2B0

Q28283107-077AA2F1-767C-4F0F-816D-A0F6CE34CB40

Q28283107-0D968192-F230-48B7-B138-E792DCB9A2D0

Q28283107-2B281EFF-C7FE-4B4B-994F-CEFDE531F50B

Q28283107-3EA84A06-8228-4784-951B-8B4FF25E279E

Q28283107-9D158180-87D4-450A-A6C5-84223F76ABDE

Q28283107-EC373DED-D2B1-4023-8D23-03E5AE4BF3FA

P304

Q28283107-052A2AC9-BCC2-4017-AC1F-C57BFB982C54

Q28283107-AA037187-4C50-4FD5-B9E4-1F8E7FD2DD20

P31

Q28283107-F2DE0DC9-2F97-472B-811F-BAC05DBE3A03

P3181

Q28283107-CE9188F5-8527-47FB-A383-5AD7C7C2F0FB

P356

Q28283107-2709FC0B-AD3E-44E7-B35D-D940651DC8AD

P407

Q28283107-264B3EBA-99F3-45CC-BBD8-A5022AB4B19F

P433

Q28283107-A4F2751D-0FD6-4154-8616-3A94E49B2CFA

Q28283107-B1CFFF79-C912-48C4-BEC7-C55D1BFA761B

P478

Q28283107-C2170ED3-998D-43DE-BAEB-356C5508C168

P50

Q28283107-2279DB39-FD54-45C2-B339-66C745AE0FC5

Q28283107-64A54236-8B3A-43FF-B0AE-DFE47805BA88

Q28283107-C79F2A51-6A93-474A-840F-62D66A245173

P577

Q28283107-634F81FC-5B28-463D-832E-6730CB5C0C55

Q28283107-7FD813AB-63A0-4CF6-B10F-237D4A40BCB7

P698

Q28283107-60FDF2D9-44CC-4BA4-9AC3-380BC9C7C157

P921

Q28283107-3D8DCFBD-1B4C-4E11-BCDA-BF0CEA4CD2BE

Q28283107-4DDC2708-FCC7-4E26-A80F-429A183A6158

Q28283107-6670F24B-133A-4079-B8BD-A4A158A3A9ED

P3181

P356

JCP.09M05117YEL

P1433

The Journal of Clinical Psychiatry

P1476

Adjuvant Aspirin Therapy Reduces Symptoms of Schizophrenia Spectrum Disorders

@en

Adjuvant aspirin therapy reduc ...... lind, placebo-controlled trial

@en

P2093

Cobi J Heijnen

http://www.w3.org/2001/XMLSchema#string

Cobi J. Heijnen

http://www.w3.org/2001/XMLSchema#string

Diederick E Grobbee

http://www.w3.org/2001/XMLSchema#string

Huibert Burger

http://www.w3.org/2001/XMLSchema#string

Jean-Paul Selten

http://www.w3.org/2001/XMLSchema#string

René S Kahn

http://www.w3.org/2001/XMLSchema#string

Wijnand Laan

http://www.w3.org/2001/XMLSchema#string

P304

520-527

http://www.w3.org/2001/XMLSchema#string

520-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

902699

http://www.w3.org/2001/XMLSchema#string

P356

10.4088/JCP.09M05117YEL

http://www.w3.org/2001/XMLSchema#string

P407

P433

05

http://www.w3.org/2001/XMLSchema#string

5

http://www.w3.org/2001/XMLSchema#string

P478

71

http://www.w3.org/2001/XMLSchema#string

P50

Jean-Paul Selten

Diederick E Grobbee

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20492850

http://www.w3.org/2001/XMLSchema#string

P921